Glucagon, Glucagon-like Peptide (e.g., Glp-1, Glp-2, Etc.) Or Derivative Patents (Class 514/11.7)
-
Publication number: 20140294977Abstract: The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.Type: ApplicationFiled: November 21, 2012Publication date: October 2, 2014Applicant: DURECT CORPORATIONInventors: Michael Sekar, Su Il Yum, Felix Theeuwes, William van Osdol
-
Publication number: 20140296131Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Patent number: 8846625Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Assignee: 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Patent number: 8846618Abstract: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.Type: GrantFiled: May 24, 2010Date of Patent: September 30, 2014Assignee: Novo Nordisk A/SInventors: James M. Flink, Silke Møller Larsen, Simon Bjerregaard Jensen, Dorthe Kot Engelund
-
Publication number: 20140287998Abstract: Glucagon is formulated in hydrochloric acid buffered, mannitol containing formulations that can be readily lyophilized and rapidly reconstituted for use in dual chamber cartridges and auto-injector device technology.Type: ApplicationFiled: December 7, 2012Publication date: September 25, 2014Inventors: Richard W. Rylander, JR., Solomon Tse
-
Publication number: 20140271888Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: ApplicationFiled: April 11, 2014Publication date: September 18, 2014Applicant: MannKind CorporationInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Patent number: 8815802Abstract: The invention relates to a GLP-1 analog which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1(7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogs and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.Type: GrantFiled: December 16, 2010Date of Patent: August 26, 2014Assignee: Novo Nordisk A/SInventors: Christoph Kalthoff, Jesper Lau, Jane Spetzler, Patrick William Garibay, Jacob Kofoed, Lars Linderoth
-
Publication number: 20140235535Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.Type: ApplicationFiled: July 3, 2012Publication date: August 21, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
-
Publication number: 20140227359Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: ApplicationFiled: January 8, 2014Publication date: August 14, 2014Applicant: MannKind CorporationInventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 8802622Abstract: The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides.Type: GrantFiled: March 18, 2011Date of Patent: August 12, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Masaru Matsumoto, Shuji Takeda, Kyohei Nobori
-
Publication number: 20140221283Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: August 7, 2014Applicant: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley
-
Publication number: 20140221282Abstract: There are provided compounds having two peptide hormones bound to a central water-soluble polymeric spacer and methods of use thereof.Type: ApplicationFiled: May 24, 2012Publication date: August 7, 2014Inventors: Chengzao Sun, Behrouz Bruce Forood
-
Publication number: 20140221280Abstract: Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are providedType: ApplicationFiled: July 4, 2011Publication date: August 7, 2014Applicant: IMPERIAL INNOVATIONS LIMITEDInventor: Stephen Robert Bloom
-
Publication number: 20140220134Abstract: The disclosure provides methods for treating diabetes, treating overweight, treating obesity, reducing body weight, treating cardiovascular diseases, treating fatty liver diseases, treating gastrointestinal diseases, and treating neurodegenerative diseases through the once monthly administration of pharmaceutical formulations containing a non-aqueous carrier and GLP-1 receptor agonists that provides therapeutically effective plasma concentration levels of the GLP-1 receptor agonists over the course of a month.Type: ApplicationFiled: June 21, 2012Publication date: August 7, 2014Applicants: Astrazeneca Pharamceuticals LP, Amylin Pharmaceuticals LLCInventors: Matthew L. Zierhut, Brenda B. Cirincione
-
Publication number: 20140221281Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: August 7, 2014Applicant: SanofiInventors: Torsten HAACK, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140213518Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: November 5, 2013Publication date: July 31, 2014Applicant: 1149336 Ontario Inc.Inventor: Daniel J. Drucker
-
Publication number: 20140213513Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140212472Abstract: Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).Type: ApplicationFiled: July 5, 2012Publication date: July 31, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Joel F. Habener, Eva Tomas-Falco
-
Publication number: 20140206609Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 24, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140206608Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 24, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140206616Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.Type: ApplicationFiled: August 28, 2012Publication date: July 24, 2014Applicant: Chong Kun Dang Pharmaceutical Corp.Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki
-
Publication number: 20140206607Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: July 24, 2014Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Richard D. Dimarchi, David L. Smiley, Bin S. Yang
-
Publication number: 20140206615Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: NOVO NORDISK A/SInventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
-
Publication number: 20140200183Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.Type: ApplicationFiled: March 21, 2014Publication date: July 17, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: David R. HATHAWAY, Alain D. BARON
-
Patent number: 8778403Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: GrantFiled: September 3, 2013Date of Patent: July 15, 2014Assignee: Mannkind CorporationInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Publication number: 20140193365Abstract: The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicant: Durect CorporationInventors: William W. van Osdol, Su Il Yum, Felix Theeuwes, Michael Sekar, John W. Gibson, Keith E. Branham, Huey-Ching Su
-
Publication number: 20140187489Abstract: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyl and C6 to C21 alkenoyl.Type: ApplicationFiled: May 25, 2012Publication date: July 3, 2014Applicant: ARISGEN SAInventors: Paolo Botti, Sylvie Tchertchian
-
Publication number: 20140187490Abstract: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicants: Rose Pharma A/S, MannKind CorporationInventors: Peter Richardson, Edna Kenny, Per Hellstrom, Marshall L. Grant, Grayson W. Stowell, Scott Daniels, Anthony Smithson, Stephanie Greene
-
Patent number: 8765668Abstract: The present invention relates to process to prepare ?-aminobutyryl compounds having ?-amino acid core structural moieties and optionally having ?-phenyl and/or heterocyclic structural moieties. Such compounds are useful as key structure framework of modern drug chemistry.Type: GrantFiled: June 3, 2011Date of Patent: July 1, 2014Assignee: Lek Pharmaceuticals D.D.Inventors: Damjan Sterk, Matjaz Ustar, Marko Zlicar
-
Patent number: 8765669Abstract: Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.Type: GrantFiled: June 15, 2009Date of Patent: July 1, 2014Assignee: Glytech, Inc.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Naohiro Hayashi, Kazuyuki Ishii, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Patent number: 8759290Abstract: The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding motif for action on a GLP-1 receptor and at least one oligomer conjugation site for binding with at least one oligomer, wherein the oligomer includes a polyethylene glycol moiety (PEG), and/or alkyl moiety.Type: GrantFiled: October 18, 2006Date of Patent: June 24, 2014Assignee: Biocon LimitedInventor: Kenneth D. James
-
Patent number: 8759291Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: April 5, 2011Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Andrew A. Young, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20140171364Abstract: The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 21, 2014Publication date: June 19, 2014Inventors: Steven Prestrelski, Wei-Jie Fang, John F. Carpenter, John Kinzell
-
Publication number: 20140171370Abstract: The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.Type: ApplicationFiled: December 6, 2013Publication date: June 19, 2014Applicant: PhaseBio Pharmaceuticals, Inc.Inventors: Susan Arnold, Christopher Prior
-
Publication number: 20140171362Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: Xeris Pharmaceuticals, Inc.Inventors: Steven Prestrelski, John Kinzell
-
Publication number: 20140162943Abstract: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce ?-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.Type: ApplicationFiled: January 28, 2014Publication date: June 12, 2014Applicants: ASTRAZENECA PHARMACEUTICALS, LP, AMYLIN PHARMACEUTICALS, LLCInventors: Josue ALFARO-LOPEZ, Abhinandini SHARMA, Soumitra S. GHOSH
-
Publication number: 20140154214Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: ApplicationFiled: February 4, 2014Publication date: June 5, 2014Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Patent number: 8729019Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.Type: GrantFiled: July 6, 2010Date of Patent: May 20, 2014Assignee: Mannkind CorporationInventors: Keith A. Oberg, Joseph Sulner
-
Patent number: 8729018Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.Type: GrantFiled: March 12, 2013Date of Patent: May 20, 2014Assignee: Duke UniversityInventor: Ashutosh Chilkoti
-
Patent number: 8729017Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: GrantFiled: June 12, 2012Date of Patent: May 20, 2014Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, David L. Smiley, Bin Yang
-
Publication number: 20140121159Abstract: The present disclosure provides inter alia conjugates of formula (I): wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors.Type: ApplicationFiled: December 3, 2013Publication date: May 1, 2014Applicant: SmartCells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20140121154Abstract: This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: ApplicationFiled: April 5, 2012Publication date: May 1, 2014Applicant: Longevity Biotech, Inc.Inventors: Scott Shandler, Samuel H. Gellman
-
Patent number: 8697644Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.Type: GrantFiled: March 9, 2012Date of Patent: April 15, 2014Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven Prestrelski, John Kinzell
-
Patent number: 8697648Abstract: The 30 amino acid peptide GLP-1 has been integrated into the stable host protein human calbindin D9k. The fusion protein binds to GLP-1R. The fusion protein agents can be useful for both diabetes treatment and GLP-1R receptor targeting MR imaging. The fusion protein comprises a first peptide that selectively binds to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone and may further comprise a detectable label. The first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 (GLP-1)(7-36), or glucagon-like peptide-1 (GLP-1) (9-36), or a conservative variant thereof.Type: GrantFiled: October 20, 2010Date of Patent: April 15, 2014Assignee: Georgia State University Research Foundation, Inc.Inventors: Zhi-Ren Liu, Jie Yang, Bing Xu, Wangda Zhou, Shenghui Xue
-
Publication number: 20140100156Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicant: SANOFIInventors: Torsten HAACK, Michael WAGNER, Bernd HENKEL, Siegfried STENGELIN, Andreas EVERS, Martin BOSSART
-
Patent number: 8691763Abstract: The present invention provides methods for treating, preventing and/or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and/or at least one GLP-1 agonist.Type: GrantFiled: May 4, 2011Date of Patent: April 8, 2014Assignee: GlaxoSmithKline LLCInventors: Beat M. Jucker, John J. Lepore, Eric J. Olson
-
Publication number: 20140094407Abstract: The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. a peptide such as leuprolide, via the vagina to a female mammal. In some embodiments, the invention also relates to methods for the treatment of obesity and eating disorders, diabetes, multiple sclerosis (MS), endometriosis, uterine fibroids, polycystic ovarian disease, various cancers such as breast cancer, acne, hirsutism, microbial or fungal or viral infections such as bacterial vaginosis or AIDS/HIV, and chronic diseases using a disclosed vaginal device.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicant: Combinent Biomedical Systems, Inc.Inventors: Eyal S. Ron, William F. Crowley, JR., Robert S. Langer, Surajit K. Biswas, Quentin Baca, Armen Tashjian
-
Publication number: 20140087996Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: ApplicationFiled: December 4, 2013Publication date: March 27, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK
-
Publication number: 20140086910Abstract: The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of Alzheimer's diseases.Type: ApplicationFiled: August 29, 2013Publication date: March 27, 2014Applicant: DARA BIOSCIENCES, INC.Inventor: Mary Katherine Delmedico
-
Patent number: 8680315Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.Type: GrantFiled: June 26, 2009Date of Patent: March 25, 2014Assignee: Prolynx, LLCInventors: Daniel V. Santi, Gary W. Ashley